INSULIN RESISTANCE, POLYCYSTIC OVARIAN DISEASE AND ACANTHOSIS NIGRICANS

胰岛素抵抗、多囊卵巢疾病和黑棘皮症

基本信息

  • 批准号:
    6566702
  • 负责人:
  • 金额:
    $ 27.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-12-01 至 2002-11-30
  • 项目状态:
    已结题

项目摘要

Acanthosis nigricans is a cutaneous manifestation of insulin resistance. This project aims to determine specific mechanisms that cause insulin resistance in the syndrome of acanthosis nigricans which most commonly presents at puberty in females with obesity and oligomenorrhea. In these young adolescents glucose tolerance is often normal in spite of severe insulin resistance. But recent data suggests that progressive loss of compensatory insulin hypersecretion is frequent and there is eventual development of type 2 diabetes mellitus. Other data suggests a markedly increased prevalence of acanthosis nigricans in some ethnic minorities. The long term goals are to (a) fully characterize the nature of the resistance to insulin, (b) delineate the relative importance of genetic and acquired factors in this syndrome, (c) determine the relationship of the ovarian dysfunction and the skin lesions to insulin resistance, and (d)determine what therapy can be effective. The goals are to test the following hypotheses over the next three years. (1) Severe insulin resistance directly affects insulin action in all insulin responsive tissues. Alternatively, this might be limited to insulin responsive glucose uptake in muscle and fat. Stable isotope-labeled glucose and glycerol infusions during euglycemic clamp studies will characterize the dose response curve for insulin-stimulated glucose uptake into muscle, insulin suppression of hepatic glucose output, and insulin suppression of adipocyte glycerol release. (2) The natural course of this insulin resistance syndrome is to lose pancreatic beta cell reserve and eventually develop overt type 2 diabetes. This will be tested by yearly follow-up assessments in all identified patients, consisting of determing glucose tolerance and quantitating insulin secretion and insulin responsiveness. Additional data will be maintained on the course of the obesity, ovaian dysfunction, hypertension, and hyperlipidemia. (3) Parents and siblings will be affected if a specific defect is identified in the proband. Parents and siblings of six severly affected subjects will be evaluated for hyperininsulinemia and in vivo insulin resistance and biochemical characterization will be performed. These proposed experiments may provide important insights into mechanisms of defective insulin action in other common health problems such as obesity and type 2 diabetes mellitus.
黑色素沉着症是胰岛素抵抗的皮肤表现。该项目旨在确定导致黑棘皮病综合征胰岛素抵抗的具体机制,黑棘皮病最常见于青春期肥胖和月经过少的女性。 在这些年轻的青少年中,尽管存在严重的胰岛素抵抗,但葡萄糖耐量通常是正常的。 但最近的数据表明,代偿性胰岛素分泌过多的进行性丧失是频繁的,并最终发展为2型糖尿病。 其他数据表明,在一些少数民族中,黑棘皮病的患病率明显增加。长期目标是(a)充分描述胰岛素抵抗的性质,(B)描述遗传和获得性因素在该综合征中的相对重要性,(c)确定卵巢功能障碍和皮肤病变与胰岛素抵抗的关系,和(d)确定什么治疗是有效的。 目标是在未来三年内测试以下假设。 (1)严重的胰岛素抵抗直接影响所有胰岛素反应组织中的胰岛素作用。 或者,这可能限于肌肉和脂肪中的胰岛素响应性葡萄糖摄取。正常血糖钳夹研究期间稳定同位素标记的葡萄糖和甘油输注将表征胰岛素刺激的葡萄糖摄入肌肉、胰岛素抑制肝脏葡萄糖输出和胰岛素抑制脂肪细胞甘油释放的剂量响应曲线。 (2)这种胰岛素抵抗综合征的自然过程是失去胰腺β细胞储备,最终发展为明显的2型糖尿病。 这将通过每年对所有确定的患者进行随访评估进行测试,包括确定葡萄糖耐量和定量胰岛素分泌和胰岛素反应性。 将保留关于肥胖、卵巢功能障碍、高血压和高脂血症病程的其他数据。 (3)如果在先证者中发现特定的缺陷,父母和兄弟姐妹将受到影响。 将评价6例严重受累受试者的父母和兄弟姐妹的高胰岛素血症和体内胰岛素抵抗,并进行生化表征。 这些拟议的实验可能会提供重要的见解,在其他常见的健康问题,如肥胖和2型糖尿病的缺陷胰岛素作用的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES A STUART其他文献

CHARLES A STUART的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES A STUART', 18)}}的其他基金

Mechanisms by which strength training ameliorates the Metabolic Syndrome
力量训练改善代谢综合症的机制
  • 批准号:
    8006750
  • 财政年份:
    2010
  • 资助金额:
    $ 27.93万
  • 项目类别:
Mechanisms by which strength training ameliorates the Metabolic Syndrome
力量训练改善代谢综合症的机制
  • 批准号:
    7522195
  • 财政年份:
    2008
  • 资助金额:
    $ 27.93万
  • 项目类别:
Mechanisms by which exercise training ameliorates the metabolic syndrome
运动训练改善代谢综合征的机制
  • 批准号:
    8035605
  • 财政年份:
    2008
  • 资助金额:
    $ 27.93万
  • 项目类别:
INSULIN RESISTANCE, POLYCYSTIC OVARIAN DISEASE AND ACANTHOSIS NIGRICANS
胰岛素抵抗、多囊卵巢疾病和黑棘皮症
  • 批准号:
    6413641
  • 财政年份:
    2000
  • 资助金额:
    $ 27.93万
  • 项目类别:
INSULIN RESISTANCE, POLYCYSTIC OVARIAN DISEASE AND ACANTHOSIS NIGRICANS
胰岛素抵抗、多囊卵巢疾病和黑棘皮症
  • 批准号:
    6305262
  • 财政年份:
    1999
  • 资助金额:
    $ 27.93万
  • 项目类别:
DISUSE MUSCLE ATROPHY--MECHANISM OF DEVELOPMENT
废用性肌萎缩——发展机制
  • 批准号:
    6115159
  • 财政年份:
    1998
  • 资助金额:
    $ 27.93万
  • 项目类别:
ALPHA2 ADRENERGIC RECEPTOR DYSFUNCTION IN PATIENTS W/ REGIONAL LIPOAT
区域 LIPOAT 患者的 ALPHA2 肾上腺素能受体功能障碍
  • 批准号:
    6264367
  • 财政年份:
    1998
  • 资助金额:
    $ 27.93万
  • 项目类别:
INSULIN RESISTANCE, POLYCYSTIC OVARIAN DISEASE AND ACANTHOSIS NIGRICANS
胰岛素抵抗、多囊卵巢疾病和黑棘皮症
  • 批准号:
    6115141
  • 财政年份:
    1998
  • 资助金额:
    $ 27.93万
  • 项目类别:
DISUSE MUSCLE ATROPHY--MECHANISM OF DEVELOPMENT
废用性肌萎缩——发展机制
  • 批准号:
    6276394
  • 财政年份:
    1997
  • 资助金额:
    $ 27.93万
  • 项目类别:
DISUSE MUSCLE ATROPHY--MECHANISM OF DEVELOPMENT
废用性肌萎缩——发展机制
  • 批准号:
    6246314
  • 财政年份:
    1997
  • 资助金额:
    $ 27.93万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.93万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 27.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了